
A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study shows. The vaccine could help liver cancer patients live longer, as fewer than one in 10 survive five years after their diagnosis, the researchers noted. In fact, about 8%… read on > read on >